Hutchison China MediTech (HCM) continues to move swiftly towards its goal of globalisation of its innovative oncology assets and building a fully integrated oncology business in China. Regarding the latter, the amended deal terms with Eli Lilly on fruquintinib is a huge positive, which will enable HCM to fully leverage its existing China oncology sales and marketing infrastructure across two assets: Elunate for CRC and surufatinib for NET. The recently reported interim results highlight furth
07 Aug 2020
Hutchison China MediTech - To China and beyond
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hutchison China MediTech - To China and beyond
HUTCHMED (China) Limited (HCM:LON) | 267 2.7 0.4% | Mkt Cap: 2,326m
- Published:
07 Aug 2020 -
Author:
Dr Susie Jana -
Pages:
7
Hutchison China MediTech (HCM) continues to move swiftly towards its goal of globalisation of its innovative oncology assets and building a fully integrated oncology business in China. Regarding the latter, the amended deal terms with Eli Lilly on fruquintinib is a huge positive, which will enable HCM to fully leverage its existing China oncology sales and marketing infrastructure across two assets: Elunate for CRC and surufatinib for NET. The recently reported interim results highlight furth